These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38182887)

  • 1. LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus.
    Xu ZS; Du WT; Wang SY; Wang MY; Yang YN; Li YH; Li ZQ; Zhao LX; Yang Y; Luo WW; Wang YY
    Cell Res; 2024 Feb; 34(2):140-150. PubMed ID: 38182887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crimean-Congo haemorrhagic fever virus uses LDLR to bind and enter host cells.
    Monteil VM; Wright SC; Dyczynski M; Kellner MJ; Appelberg S; Platzer SW; Ibrahim A; Kwon H; Pittarokoilis I; Mirandola M; Michlits G; Devignot S; Elder E; Abdurahman S; Bereczky S; Bagci B; Youhanna S; Aastrup T; Lauschke VM; Salata C; Elaldi N; Weber F; Monserrat N; Hawman DW; Feldmann H; Horn M; Penninger JM; Mirazimi A
    Nat Microbiol; 2024 Jun; 9(6):1499-1512. PubMed ID: 38548922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38.
    Mishra AK; Moyer CL; Abelson DM; Deer DJ; El Omari K; Duman R; Lobel L; Lutwama JJ; Dye JM; Wagner A; Chandran K; Cross RW; Geisbert TW; Zeitlin L; Bornholdt ZA; McLellan JS
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31996434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside-Modified mRNA Vaccines Protect IFNAR
    Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
    J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
    Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
    J Virol; 2017 May; 91(10):. PubMed ID: 28250124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1.
    Hu YL; Zhang LQ; Liu XQ; Ye W; Zhao YX; Zhang L; Qiang ZX; Zhang LX; Lei YF; Jiang DB; Cheng LF; Zhang FL
    Front Cell Infect Microbiol; 2023; 13():1121163. PubMed ID: 37026060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crimean-Congo hemorrhagic fever virus utilizes a clathrin- and early endosome-dependent entry pathway.
    Garrison AR; Radoshitzky SR; Kota KP; Pegoraro G; Ruthel G; Kuhn JH; Altamura LA; Kwilas SA; Bavari S; Haucke V; Schmaljohn CS
    Virology; 2013 Sep; 444(1-2):45-54. PubMed ID: 23791227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The low-density lipoprotein receptor and apolipoprotein E associated with CCHFV particles mediate CCHFV entry into cells.
    Ritter M; Canus L; Gautam A; Vallet T; Zhong L; Lalande A; Boson B; Gandhi A; Bodoirat S; Burlaud-Gaillard J; Freitas N; Roingeard P; Barr JN; Lotteau V; Legros V; Mathieu C; Cosset FL; Denolly S
    Nat Commun; 2024 May; 15(1):4542. PubMed ID: 38806525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins.
    Bertolotti-Ciarlet A; Smith J; Strecker K; Paragas J; Altamura LA; McFalls JM; Frias-Stäheli N; García-Sastre A; Schmaljohn CS; Doms RW
    J Virol; 2005 May; 79(10):6152-61. PubMed ID: 15858000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleocapsid protein-specific monoclonal antibodies protect mice against Crimean-Congo hemorrhagic fever virus.
    Garrison AR; Moresco V; Zeng X; Cline CR; Ward MD; Ricks KM; Olschner SP; Cazares LH; Karaaslan E; Fitzpatrick CJ; Bergeron É; Pegan SD; Golden JW
    Nat Commun; 2024 Feb; 15(1):1722. PubMed ID: 38409240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.
    Hawman DW; Meade-White K; Haddock E; Habib R; Scott D; Thomas T; Rosenke R; Feldmann H
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31292241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.
    Garrison AR; Shoemaker CJ; Golden JW; Fitzpatrick CJ; Suschak JJ; Richards MJ; Badger CV; Six CM; Martin JD; Hannaman D; Zivcec M; Bergeron E; Koehler JW; Schmaljohn CS
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005908. PubMed ID: 28922426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat Shock Protein 70 Family Members Interact with Crimean-Congo Hemorrhagic Fever Virus and Hazara Virus Nucleocapsid Proteins and Perform a Functional Role in the Nairovirus Replication Cycle.
    Surtees R; Dowall SD; Shaw A; Armstrong S; Hewson R; Carroll MW; Mankouri J; Edwards TA; Hiscox JA; Barr JN
    J Virol; 2016 Oct; 90(20):9305-16. PubMed ID: 27512070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryo-EM structure of glycoprotein C from Crimean-Congo hemorrhagic fever virus.
    Li N; Rao G; Li Z; Yin J; Chong T; Tian K; Fu Y; Cao S
    Virol Sin; 2022 Feb; 37(1):127-137. PubMed ID: 35234630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crimean-Congo hemorrhagic fever virus replication imposes hyper-lipidation of MAP1LC3 in epithelial cells.
    Moroso M; Verlhac P; Ferraris O; Rozières A; Carbonnelle C; Mély S; Endtz HP; Peyrefitte CN; Paranhos-Baccalà G; Viret C; Faure M
    Autophagy; 2020 Oct; 16(10):1858-1870. PubMed ID: 31905032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine mapping epitope on glycoprotein Gc from Crimean-Congo hemorrhagic fever virus.
    Zhang J; Simayi A; Wang M; Moming A; Xu W; Wang C; Li Y; Ding J; Deng F; Zhang Y; Sun S
    Comp Immunol Microbiol Infect Dis; 2019 Dec; 67():101371. PubMed ID: 31627038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crimean-Congo hemorrhagic fever virus entry into host cells occurs through the multivesicular body and requires ESCRT regulators.
    Shtanko O; Nikitina RA; Altuntas CZ; Chepurnov AA; Davey RA
    PLoS Pathog; 2014 Sep; 10(9):e1004390. PubMed ID: 25233119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus.
    Zivcec M; Scholte FE; Spiropoulou CF; Spengler JR; Bergeron É
    Viruses; 2016 Apr; 8(4):106. PubMed ID: 27110812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus.
    Wang Q; Cao R; Li L; Liu J; Yang J; Li W; Yan L; Wang Y; Yan Y; Li J; Deng F; Zhou Y; Wang M; Zhong W; Hu Z
    Antiviral Res; 2022 Mar; 199():105273. PubMed ID: 35257725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular (ticks) and serological (humans) study of Crimean-Congo hemorrhagic fever virus in the Iberian Peninsula, 2013-2015.
    Palomar AM; Portillo A; Santibáñez S; García-Álvarez L; Muñoz-Sanz A; Márquez FJ; Romero L; Eiros JM; Oteo JA
    Enferm Infecc Microbiol Clin; 2017; 35(6):344-347. PubMed ID: 28291670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.